Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Assets: 2015-2024

Historic Current Assets for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $603.1 million.

  • Syndax Pharmaceuticals' Current Assets rose 27.73% to $529.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $529.8 million, marking a year-over-year increase of 27.73%. This contributed to the annual value of $603.1 million for FY2024, which is 3.82% up from last year.
  • Syndax Pharmaceuticals' Current Assets amounted to $603.1 million in FY2024, which was up 3.82% from $580.9 million recorded in FY2023.
  • In the past 5 years, Syndax Pharmaceuticals' Current Assets ranged from a high of $603.1 million in FY2024 and a low of $298.9 million during FY2020.
  • Moreover, its 3-year median value for Current Assets was $580.9 million (2023), whereas its average is $557.9 million.
  • Data for Syndax Pharmaceuticals' Current Assets shows a peak YoY surged of 379.48% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Syndax Pharmaceuticals' Current Assets stood at $298.9 million in 2020, then spiked by 50.03% to $448.4 million in 2021, then climbed by 9.23% to $489.8 million in 2022, then increased by 18.60% to $580.9 million in 2023, then increased by 3.82% to $603.1 million in 2024.